Mohamed Rahman, MD
Critical Care Medicine · Brooklyn, NYNPI 1942244348
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 81.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2024 at $100 and has fallen 83.5% since, to $17 in 2025. That places this record below the midpoint for critical care medicine clinicians in NY, where the typical reported total is $204.
Across 9 payments — averaging $22.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$163
- Optinose US, Inc.$20
- Medtronic$16
What the payments were for
- Food & beverage$199100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $163 |
| Optinose US, Inc. | 1 | $20 |
| Medtronic | 1 | $16 |
How this compares
$199 in reported general payments places this provider in the 45th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProcritEpoetin Alfa | 109 | $118,816 |
| SantylCollagenase Clostridium Hist. | 81 | $90,536 |
| EliquisApixaban | 211 | $60,512 |
| DescovyEmtricitabine/Tenofov Alafenam | 13 | $30,421 |
| Tetrabenazine | 24 | $27,890 |
| RetacritEpoetin Alfa-Epbx | 52 | $26,228 |
| TrulicityDulaglutide | 20 | $15,361 |
| EntrestoSacubitril/Valsartan | 43 | $14,308 |
| JanuviaSitagliptin Phosphate | 45 | $13,493 |
| Levetiracetam | 248 | $11,734 |
| JardianceEmpagliflozin | 26 | $8,015 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 107 | $7,778 |
| LokelmaSodium Zirconium Cyclosilicate | 20 | $6,879 |
| InvokanaCanagliflozin | 11 | $6,579 |
| Midodrine Hcl | 77 | $6,183 |
Paid to pharmacies, not to this prescriber.
Other critical care medicine in Brooklyn
- Joshua RosenbergBrooklyn$881K
- Mohammad ZamanBrooklyn$13K
- Yizhak KupferBrooklyn$8K
- Chetana PendkarBrooklyn$7K
- Steven BadinBrooklyn$5K
- Daniel BuchneaBrooklyn$4K
- Samir FahmyBrooklyn$4K
- Alibel BelloBrooklyn$4K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.